SFOSF (Shanghai Fosun Pharmaceutical (Group) Co) Cash And Cash Equivalents : $1,892 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Cash And Cash Equivalents?

Shanghai Fosun Pharmaceutical (Group) Co's quarterly cash and cash equivalents declined from Sep. 2024 ($1,908.98 Mil) to Dec. 2024 ($1,857.50 Mil) but then increased from Dec. 2024 ($1,857.50 Mil) to Mar. 2025 ($1,892.04 Mil).

Shanghai Fosun Pharmaceutical (Group) Co's annual cash and cash equivalents declined from Dec. 2022 ($2,329.61 Mil) to Dec. 2023 ($1,917.82 Mil) and declined from Dec. 2023 ($1,917.82 Mil) to Dec. 2024 ($1,857.50 Mil).

Shanghai Fosun Pharmaceutical (Group) Co Cash And Cash Equivalents Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Cash And Cash Equivalents Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,523.37

1,619.84

2,329.61

1,917.82

1,857.50

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,805.79	1,940.87	1,908.98	1,857.50	1,892.04

Shanghai Fosun Pharmaceutical (Group) Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Shanghai Fosun Pharmaceutical (Group) Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (OTCPK:SFOSF) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

02196:Hong Kong 08HH:Germany 08HH:Germany 600196:China

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.